免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

MK-8776 (SCH 900776)

目录号：S2735

仅限科研使用

MK-8776 (SCH 900776)是一种选择性Chk1抑制剂，无细胞试验中IC50为3 nM，比作用于Chk2选择性高500倍。Phase 2。

CAS: 891494-63-6

规格	价格	库存
10mM (1mL in DMSO)	RMB 1921.21	现货
5mg	RMB 1733.35	现货
50mg	RMB 7966.05	现货
大包装	有超大折扣

今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的MK-8776 (SCH 900776)发表文献55篇：

产品安全说明书

Chk抑制剂选择性比较

生物活性

产品描述

MK-8776 (SCH 900776)是一种选择性Chk1抑制剂，无细胞试验中IC50为3 nM，比作用于Chk2选择性高500倍。Phase 2。

靶点

Chk1 ^[1] (Cell-free assay)	CDK2 ^[1] (Cell-free assay)
3 nM	0.16 μM

体外研究

SCH 900776是Chk2和CDK2的低效抑制剂，IC50分别为1.5 μM 和 0.16 μM。SCH 900776对细胞色素P450人肝微粒体亚型1A2，2C9，2C19，2D6，和3A4没有显著的抑制作用。羟基脲下暴露24小时后，SCH 900776诱导DNA复制能力剂量依赖性损失。SCH 900776增强γ-H2AX对羟基脲，5-氟尿嘧啶，和阿糖孢苷的响应。与抗代谢物结合，SCH 900776在2小时内诱导γ-H2AX的累积，表明复制叉瓦解，并且双链DNA断裂。此外，SCH 900776以剂量依赖的方式抑制Chk1 pS296自磷酸化的积累。增殖的WS1细胞暴露于SCH 900776，与Chk1 pS345快速的，剂量依赖性聚集相关，表明正常细胞的循环群诱导Chk1 pS345在暴露于SCH 900776后，是一部分无效循环，这也许通过AT-家族激酶和DNA-PK驱动。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

U251	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T6clIxOC9{MECwJI5O	M{f5N\|I1KGh?		Mnrj[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n	M1HRS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
HCT115	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:3NlAxNzJyMECgcm0>	NVLLO3RbOjRiaB?=		M{C0fYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?=	NHT0S4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
SW620	NHzaWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInBTo4zODBxMkCwNEBvVQ>?	MXyyOEBp		NGSzb5Zl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW=	MlO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
IGROV-1	NVL2RVNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rB[\|IxOC9{MECwJI5O	MVmyOEBp		M170OYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?=	MmjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
HCT116	NGq0bGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnKWFNNOjByL{KwNFAhdk1?	NFz6bIozPCCq		M4jTO4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR\|NUm1NlY9N2F-
MCF10A	M1j3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfUcYQzODBxMkCwNEBvVQ>?	MorVNlQhcA>?		MkfM[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n	NWSwPFM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N\|U6PTJ4PD;hQi=>
MiaPaCa-2	NH7K[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXeyNFAwOjByMDDuUS=>	Mn7tNlQhcA>?		MnPH[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
MDA-MB-231	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;oT\|FCOjByL{KwNFAhdk1?	MWCyOEBp		MVTk[YNz\WG\|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR\|NUm1NlY9N2F-
HCC2998	M2LFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLkNlAxNzJyMECgcm0>	M1fZfFI1KGh?		NHSyVJdl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW=	NWO4VXpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N\|U6PTJ4PD;hQi=>
U87	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzpWYszODBxMkCwNEBvVQ>?	NFf4TWszPCCq		MorQ[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR\|NUm1NlY9N2F-
MDA-MB-435	NVvv[ZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDMNlAxNzJyMECgcm0>	MVGyOEBp		MmPH[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n	M{PDfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
SNB19	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGSxR44zODBxMkCwNEBvVQ>?	NF\SUY4zPCCq		NGHkeoJl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW=	NVXjdppzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N\|U6PTJ4PD;hQi=>
U20S	NHLVS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTqNlAxNzJyMECgcm0>	MnfvNlQhcA>?		MoTo[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n	NWPOUYVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N\|U6PTJ4PD;hQi=>
A498	NUfrb2RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfTNlAxNzJyMECgcm0>	MViyOEBp		NX;mc4tj\GWlcnXhd4V{KHSqZTDJR\|UxKG:oIFflcYNqfGGkaX7l	M{HNdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
TK10	NVnMSHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqyNFAwOjByMDDuUS=>	NW\XSo5kOjRiaB?=		NXHySVRs\GWlcnXhd4V{KHSqZTDJR\|UxKG:oIFflcYNqfGGkaX7l	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR\|NUm1NlY9N2F-
AsPC-1	M{GxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYGzeIJEOjByL{KwNFAhdk1?	NGG2b\|IzPCCq		MUfk[YNz\WG\|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR\|NUm1NlY9N2F-
H23	NVLoc\|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXW[JM1PTByIH7N	MU[yOEBp	NFvGfGlFVVOR	M1O1XoVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{W0PUc,OjRzMUO1OFk9N2F-
H1437	NVfjTo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf2THA2ODBibl2=	MWSyOEBp	M3jnSGROW09?	NYnvfYxx\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh?	MoDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUO1OFkoRjJ2MUGzOVQ6RC:jPh?=
H1993	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnQV2dnPTByIH7N	MmK0NlQhcA>?	NX[yXYlDTE2VTx?=	M2LtOIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{W0PUc,OjRzMUO1OFk9N2F-
H1299	NFzlV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVS1NFAhdk1?	MVuyOEBp	NHn4N3VFVVOR	NF3FS5ZmdmijbnPld{B1cGViY3jlcY9{\W6\|aYTpfoF1cW:wIITvJHBOYA>?	NYq3RnhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVM2PDlpPkK0NVE{PTR7PD;hQi=>
AsPC-1	NWD3OFBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXUPGk1OTBvMUCwNEBvVQ>?	M{CxXlI1NTR6aB?=		M3y2bIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU>	NIj4WFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
MiaPaCa-2	M17JT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHzNVAuOTByMDDuUS=>	NW\xdIk4OjRvNEjo		M3G1TYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU>	NGW4O\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
BxPC-3	M{W3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DWbFExNTFyMECgcm0>	NFjyXngzPC12OHi=		MnP1[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDn[Y1kcXSjYnnu[S=>	NHP5VpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
SKOV3	NYDGUXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVKwMlMhyrWP	M{TqU\|gh\A>?		MXvz[Y5{cXSrenXzJJRp\SClZXzsJIxqdmW\|IITvJIdmdWOrdHHibY5myqB?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV2OEK2PUc,OjN3NEiyOlk9N2F-
OVCAR-8	NYXLWlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1uxSFAvOyEEtV2=	NHi5fIc5KGR?		Mln3d4Vve2m2aYrld{B1cGViY3XscEBtcW6nczD0c{Bo\W2laYThZolv\cLi	M4jvT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUS4NlY6Lz5{M{W0PFI3QTxxYU6=
MV-4-11	MoHSRZBweHSxc3nzJGF{e2G7	M3LpXFExOC15MECgcm0>	NXnt[olyPDhiaB?=		MkDRbY5lfWOnczDhdI9xfG:\|aYOg[I9{\SCmZYDlcoRmdnSueR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|NkeyNUc,OjN3M{[3NlE9N2F-
U937	NX\6Z3VtSXCxcITvd4l{KEG\|c3H5	NUT2fZpMOTByLUewNEBvVQ>?	NHezd5c1QCCq		NFrO[5BqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	NEPNTHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N\|Y4OjF:L3G+
MOLM-13	NHzncm1CeG:ydH;zbZMhSXO\|YYm=	M{TZNlExOC15MECgcm0>	NX7NdppNPDhiaB?=		MVrpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NEPCZ4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzOlczOSd-MkO1N\|Y4OjF:L3G+
A2058	MojrR4VtdCCYaXHibYxqfHliQYPzZZk>	NXjuOodnOzdwNT2zNFAhdk1?	NITtfJQ4OiCq	M3XQRWROW09?	M4\lWZJm\HWlZYOgeIhmKE2NLUG3O\|UhTUN3MNMgZpkhPS2ob3zkJJRwKGGwIHH2[ZJi\2Vib3[gOFUhdk1?	NWnYU3BFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFg3QDRpPkKzNVQ5Pjh2PD;hQi=>
H2009	M1r2WWNmdGxiVnnhZoltcXS7IFHzd4F6	M2naVlUxOCCwTR?=	NX7MOGNoPzJiaB?=	M3H0VWROW09?	MljPdoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O\|U>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF2OE[4OEc,OjNzNEi2PFQ9N2F-
Su.86.86	NX25WZhFS2WubDDWbYFjcWyrdImgRZN{[Xl?	MnfYOVAxKG6P	NFfKNoY4OiCq	MXjEUXNQ	M4DzZZJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO\|c2	NEjuWmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
HRE	M{HhdWNmdGxiVnnhZoltcXS7IFHzd4F6	NHH1fpY2ODBibl2=	MkfkO\|IhcA>?	MXXEUXNQ	M{\pepJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO\|c2	MonTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNEi2PFQoRjJ\|MUS4Olg1RC:jPh?=
HMEC	Mo[4R4VtdCCYaXHibYxqfHliQYPzZZk>	NYrMXW5rPTByIH7N	M3GzcVczKGh?	MWDEUXNQ	NXjpNVRKemW\|dXz0d{BqdiCJMT;TMZBp[XOnIHHjZ5VufWyjdHnvckBkd22kaX7l[EB4cXSqIF3LMVE4PzV?	M37pXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUS4Olg1Lz5{M{G0PFY5PDxxYU6=
U2OS	NXXwWFh5TnWwY4Tpc44hSXO\|YYm=	NILhfZQzKML3TR?=	MnLtNE0zPCCq		M1zkVYlv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczFiYYSgd4VzcW6nIEO0OUBifCCkb4ToJINwdmOnboTyZZRqd26\|IHHzJIViemy7IHHzJFIhcCCjZoTldkBi\G2rbnnzeJJifGmxbh?=	M3vub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUO3NVQ4Lz5{MkmzO\|E1PzxxYU6=
U2OS	M{PLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\vXHU5OC1zMDFCuW0>	Mmj5NlQwPDhiaB?=		NFfzSmVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7M{exOFcoRjJ{OUO3NVQ4RC:jPh?=
U937	NWGx[\|VbTnWwY4Tpc44hSXO\|YYm=	MmOzNVAxNTVyMDDuUS=>	Mnv4OEBpyqB?		NHzvWINl\WO{ZXHz[ZMhfGinIHP5eIFz[WKrbnWtbY5lfWOnZDDDbIsyKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjl4wrDhcoQheHKndnXueJMhS2SlMkXBJIRwf26{ZXf1cIF1cW:w	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh4OUi2PUc,OjJ6Nkm4Olk9N2F-
U937	NEn5SZNHfW6ldHnvckBCe3OjeR?=	NEjjfpUyODBibl2=	M2XPSlQhcMLi		M4nvPZJmfmW{c3XzJJRp\SCleYThdoFjcW6nLXnu[JVk\WRiaX7obYJqfGmxbjDv[uKhO0hvdHj5cYllcW6nIHnuZ49zeG:{YYTpc44hcW62bzDEUmE>	NHHFToM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2PVg3QSd-MkK4Olk5Pjl:L3G+
U937	MnPySpVv[3Srb36gRZN{[Xl?	NEHxXXYyODBvNUCwJI5O	M{jWWFQhcMLi		NUjWU2tIcW6mdXPld{BqdmO{ZXHz[YQheGixc4Doc5J6dGG2aX;uJI9nKEh{QWi=	M2fOOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[5PFY6Lz5{Mki2PVg3QTxxYU6=
HL-60	MkDmRZBweHSxc3nzJGF{e2G7	MmrlN\|AwOTByL{OwNEBvVQ>?	M3rHTlI1KGh?	MVTEUXNQ	MoXr[Y5p[W6lZYOgZ5l1[XKjYnnu[U1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Nkm4OlkoRjJ{OE[5PFY6RC:jPh?=
ML-1	MlfvRZBweHSxc3nzJGF{e2G7	MVmyOU82OC9zMECgcm0>	NImyVIkzPCCq	NHPIR2NFVVOR	NILRfpBmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{	NWXK[lh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
HCT116	MnzhSpVv[3Srb36gRZN{[Xl?	NWLLcY85OSEEtV2=	NFjnc4kzPCCq		NIrZfoVi[nKxZ3H0[ZMhd2ZiY3XscEBkgWOuZTDhdpJme3UEoB?=	NXrCdpZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NVA2PjBpPkKyOVExPTZyPD;hQi=>
U2OS	NX7mSYE3TnWwY4Tpc44hSXO\|YYm=	M33IWVEhyrWP	M3;CV\|I1KGh?		MXPhZpJw\2G2ZYOgc4Yh[2WubDDjfYNt\SCjcoLld5TDqA>?	M{TyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUGwOVYxLz5{MkWxNFU3ODxxYU6=
Sf9	M2q3VGZ2dmO2aX;uJIF{e2G7				NF7ibndKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzJxQ4njcIlvKEFiZYjwdoV{e2WmIHnuJIlve2WldDDT[lkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN\|NRZS2DVGCgbY5kd3Kyb4LheIlwdiCrboTvJIJqd3SrbonsZZRm\CCqaYP0c45mKEhzIHHmeIVzKDFiaIKgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSByLkG2JO69VS5?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB7NE[wO{c,OjFyOUS2NFc9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot

p-chk1(ser345) / CDC25A Cyclin E / pY15-CDK / γH2AX

27690219 26595527

体内研究

相对于gemcitabine或SCH 900776单独给药，Gemcitabine给药30分钟后，4 mg/kg SCH 900776足以诱导γ-H2AX生物标志物，而8 mg/kg增强肿瘤药效动力学和退化响应。递增剂量的SCH 900776 (16 mg/kg和32 mg/kg)诱导肿瘤响应持续改进。重要的是，在BALB/c 小鼠体内，SCH 900776的剂量与强的生物标志物活化相关，而提高的肿瘤响应与gemcitabine对血液学指标增强的毒性无关。^[1]

动物实验：^[1]	Animal Models: 皮下注射A2780 或 MiaPaCa2细胞的额雌性裸鼠 Dosages: ~50 mg/kg Administration: 腹腔内注射

参考文献	[1] Guzi TJ, et al. Mol Cancer Ther, 2011, 10(4), 591-602. [2] Montano R, et al. Mol Cancer Ther, 2012, 11(2), 427-438. [3] Schenk EL, et al. Clin Cancer Res, 2012, 18(19), 5364-5373.

溶解度（25°C）

体外


体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% propylene glycol	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	376.25
化学式	C₁₅H₁₈BrN₇
CAS号	891494-63-6
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download MK-8776 (SCH 900776) SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00779584	Completed	Drug: MK-8776\|Drug: Gemcitabine	Hodgkin Disease\|Lymphoma Non-Hodgkin\|Neoplasms	Merck Sharp & Dohme LLC	October 17 2008	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

常见问题及建议解决方法

问题 1:
I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

回答：
Our S2735 MK-8776 (SCH 900776) is R enantiomer.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):